Vertex's hepatitis C drug Incivek gains Canadian approval

08/22/2011 | Fox Business

Health Canada approved Incivek, Vertex Pharmaceuticals' treatment for genotype 1 hepatitis C in patients with compensated liver disease. Incivek, taken with ribavirin and pegylated interferon, was clinically proven to achieve a higher viral-cure rate than standard therapy.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX